An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients Grinyó, Josep; Charpentier, Bernard; Pestana, José Medina; More Grinyó, Josep; Charpentier, Bernard; Pestana, José Medina; Vanrenterghem, Yves; Vincenti, Flavio; Reyes-Acevedo, Rafael; Apanovitch, Anne Marie; Gujrathi, Sheila; Agarwal, Mamta; Thomas, Dolca; Larsen, Christian P. Less Transplantation. 90(12):1521-1527, December 27, 2010. Abstract Abstract Favorite PDF Permissions Go to Full Text of this Article Free
Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies Larsen, Christian P.; Grinyó, Josep; Medina-Pestana, José; More Larsen, Christian P.; Grinyó, Josep; Medina-Pestana, José; Vanrenterghem, Yves; Vincenti, Flavio; Breshahan, Barbara; Campistol, Josep M.; Florman, Sander; Rial, Maria del Carmen; Kamar, Nassim; Block, Alan; Di Russo, Gregory; Lin, Chen-Sheng; Garg, Pushkal; Charpentier, Bernard Less Transplantation. 90(12):1528-1535, December 27, 2010. Abstract Abstract Favorite PDF Permissions Go to Full Text of this Article Free
Islet Transplantation in Type 1 Diabetic Patients Using Calcineurin Inhibitor-Free Immunosuppressive Protocols Based on T-Cell Adhesion or Costimulation Blockade Posselt, Andrew M.; Szot, Gregory L.; Frassetto, Lynda A.; More Posselt, Andrew M.; Szot, Gregory L.; Frassetto, Lynda A.; Masharani, Umesh; Tavakol, Mehdi; Amin, Raj; McElroy, Joan; Ramos, Marissa D.; Kerlan, Robert K.; Fong, Lawrence; Vincenti, Flavio; Bluestone, Jeffrey A.; Stock, Peter G. Less Transplantation. 90(12):1595-1601, December 27, 2010. Abstract Abstract Favorite PDF Permissions Go to Full Text of this Article Free
Low Serum Mannose-Binding Lectin as a Risk Factor for New Onset Diabetes Mellitus After Renal Transplantation Ibernon, Meritxell; Moreso, Francesc; Moreno, José M.; More Ibernon, Meritxell; Moreso, Francesc; Moreno, José M.; Bestard, Oriol; Cruzado, Josep M.; Grinyó, Josep M.; Ricart, Wifredo; Fernández-Real, José M.; Serón, Daniel Less Transplantation. 88(2):272-278, July 27, 2009. Abstract Abstract Favorite PDF Permissions Go to Full Text of this Article Free
Belatacept as Immunosuppression in Patient With Recurrence of Hemolytic Uremic Syndrome After Renal Transplantation Midtvedt, Karsten; Bitter, Jan; Dørje, Christina; More Midtvedt, Karsten; Bitter, Jan; Dørje, Christina; Bjørneklett, Rune; Holdaas, Hallvard Less Transplantation. 87(12):1901-1903, June 27, 2009. Favorite PDF Permissions Free
Assessment of Belatacept-Mediated Costimulation Blockade Through Evaluation of CD80/86-Receptor Saturation Latek, Robert; Fleener, Catherine; Lamian, Vahideh; More Latek, Robert; Fleener, Catherine; Lamian, Vahideh; Kulbokas, Edward III; Davis, Patricia M.; Suchard, Suzanne J.; Curran, Mark; Vincenti, Flavio; Townsend, Robert Less Transplantation. 87(6):926-933, March 27, 2009. Abstract Abstract Favorite PDF Permissions Go to Full Text of this Article Free
Fibrogenesis in Kidney Transplantation: Potential Targets for Prevention and Therapy Djamali, Arjang; Samaniego, Millie Djamali, Arjang; Samaniego, Millie Less Transplantation. 88(10):1149-1156, November 27, 2009. Abstract Abstract Favorite PDF Permissions Go to Full Text of this Article Free
A MIXED TREATMENT COMPARISON OF EFFICACY AND CARDIOMETABOLIC SAFETY OF BELATACEPT, CYCLOSPORINE AND TACROLIMUS FOR IMMUNOSUPPRESSION THERAPY IN ADULT RENAL TRANSPLANT RECIPIENTS: 762 Goring, S.; Eyawo, O.; Mills, E. J.; More Goring, S.; Eyawo, O.; Mills, E. J.; Levy, A.; L'Italien, G. J.; Trivedi, D.; Kasiske, B. Less Transplantation. 90:75, July 27, 2010. Favorite PDF Permissions Free
OUTCOMES AS A FUNCTION OF DONOR:RECIPIENT CHARACTERISTICS FROM A PHASE III STUDY OF BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANTATION (BENEFIT): 2857 Vincenti, F.; Grinyó, J. M.; Charpentier, B.; More Vincenti, F.; Grinyó, J. M.; Charpentier, B.; Pestana, J. O.M.; Rostaing, L.; Vanrenterghem, Y.; Lin, C.; Di Russo, G.; Larsen, C. Less Transplantation. 90:175, July 27, 2010. Favorite PDF Permissions Free
SAFETY PROFILE OF BELATACEPT IN KIDNEY TRANSPLANT RECIPIENTS FROM A POOLED ANALYSIS OF PHASE II AND PHASE III STUDIES: 1417 Grinyo, J.; Charpentier, B.; Pestana, J. O.M.; More Grinyo, J.; Charpentier, B.; Pestana, J. O.M.; Vanrenterghem, Y.; Vincenti, F.; Shi, R.; Agarwal, M.; Thomas, D.; Larsen, C. Less Transplantation. 90:156, July 27, 2010. Favorite PDF Permissions Free
IMMUNOSUPPRESSION WITH BELATACEPT-BASED, CNI-AVOIDING AND STEROID-AVOIDING REGIMENS VS A TACROLIMUS-BASED, STEROID-AVOIDING REGIMEN IN KIDNEY TRANSPLANT PATIENTS: RESULTS OF A 1-YEAR, RANDOMIZED STUDY: 1436 Ferguson, R.; Vincenti, F.; Kaufman, D.; More Ferguson, R.; Vincenti, F.; Kaufman, D.; Woodle, E. S.; Marder, B.; Citterio, F.; Marks, W. H.; Dong, Y.; Agarwal, M.; Garg, P.; Grinyó, J. M. Less Transplantation. 90:156, July 27, 2010. Favorite PDF Permissions Free
SWITCH FROM A CNI- TO A BELATACEPT-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT RECIPIENTS IS SAFE AND RESULTS IN BETTER RENAL FUNCTION: 12 MONTH RESULTS FROM A PHASE II STUDY: 1446 Rostaing, L.; Nainan, G.; Rial, M. C.; More Rostaing, L.; Nainan, G.; Rial, M. C.; Steinberg, S.; Vincenti, F.; Shi, R.; Di Russo, G.; Thomas, D.; Grinyó, J. M. Less Transplantation. 90:157, July 27, 2010. Favorite PDF Permissions Free
BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANT RECIPIENTS: TWO-YEAR OUTCOMES FROM THE BENEFIT STUDY: 1374 Larsen, C.; Grinyó, J. M.; Charpentier, B.; More Larsen, C.; Grinyó, J. M.; Charpentier, B.; Pestana, J. O.M.; Kamar, N.; Vanrenterghem, Y.; Lin, C.; Di Russo, G.; Garg, P.; Vincenti, F. Less Transplantation. 90:158, July 27, 2010. Favorite PDF Permissions Free
PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF BELATACEPT IN RENAL TRANSPLANT PATIENTS: 1870 Shen, J.; Block, A.; Townsend, R.; More Shen, J.; Block, A.; Townsend, R.; You, Xiaoli X.; Shen, Y.; Zhou, S.; Geng, D.; McGirr, N.; Soucek, K.; Pursley, J.; Di Russo, G.; Kaul, S. Less Transplantation. 90:426, July 27, 2010. Favorite PDF Permissions Free
APPLICATION OF A VALIDATED LONG-TERM RENAL TRANSPLANT GRAFT SURVIVAL PREDICTION MODEL TO EXPECTED BELATACEPT PHASE III TRIAL OUTCOMES: 679 Schnitzler, M. A.; Trivedi, D.; L'Italien, G. J. Schnitzler, M. A.; Trivedi, D.; L'Italien, G. J. Less Transplantation. 90:341, July 27, 2010. Favorite PDF Permissions Free
RELATIONSHIP BETWEEN BELATACEPT EXPOSURE AND CLINICAL ENDPOINTS IN RENAL TRANSPLANT PATIENTS: 1892 Zhou, S.; Roy, A.; Shen, J.; More Zhou, S.; Roy, A.; Shen, J.; Kaul, S.; Pfister, M. Less Transplantation. 90:426, July 27, 2010. Favorite PDF Permissions Free
OUTCOMES AS A FUNCTION OF DONOR CRITERIA FROM A PHASE III STUDY OF BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANTATION (BENEFIT-EXT): 1773 Florman, S.; Durrbach, A.; Larsen, C.; More Florman, S.; Durrbach, A.; Larsen, C.; Pestana, J. M.; Vanrenterghem, Y.; Vincenti, F.; Block, A.; Garg, P.; Copley, B.; Duan, T.; Grinyó, J. M. Less Transplantation. 90:342, July 27, 2010. Favorite PDF Permissions Free
BENEFIT-RISK PROFILE OF THE BELATACEPT LI REGIMEN AT 2 YEARS IN EBV(+) KIDNEY TRANSPLANT RECIPIENTS: 3370 Vincenti, F.; Grinyo, J.; Larsen, C.; More Vincenti, F.; Grinyo, J.; Larsen, C.; Pestana, J. O.M.; Vanrenterghem, Y.; Duan, T.; Agarwal, M.; Charpentier, B. Less Transplantation. 90:649, July 27, 2010. Favorite PDF Permissions Free
